One shot, Year-Long relief: psoriasis drug shows promise for lasting clearance
NCT ID NCT04630652
First seen Nov 03, 2025 · Last updated Apr 24, 2026 · Updated 24 times
Summary
This study tests whether a single injection of risankizumab (Skyrizi) can clear psoriasis for up to 66 weeks in some patients. Researchers will analyze skin samples to understand immune changes that lead to long-term remission. The trial involves 20 adults with moderate-to-severe plaque psoriasis who have not used other psoriasis treatments recently.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Rockefeller Univesity
New York, New York, 10065, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
VA Northern California Health Care System
Sacramento, California, 95655, United States
Conditions
Explore the condition pages connected to this study.